Dr. Reddy’s Laboratories Limited (EHP)(製薬・医療分野):企業のM&A・提携動向

◆英語タイトル:Dr. Reddy's Laboratories Limited (EHP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆発行会社/調査会社:GlobalData
◆商品コード:GDPH28920D
◆発行日:2014年5月29日
◆調査対象地域:インド
◆ページ数:73
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Dr. Reddy’s Laboratories Limited (EHP)(製薬・医療分野):企業のM&A・提携動向]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Summary

Dr. Reddy’s Laboratories Limited (Dr. Reddy’s) is a pharmaceutical company. The company manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company’s generic products are used for the treatment of conditions such as gastrointestinal disorders, cardiovascular diseases, diabetes, cancer, pain, infectious diseases and pediatrics. The company provides more than 150 products. Its active pharmaceutical ingredients include agomelatine, alendronate sodium, amlodipine, aprepitant, aripiprazole, azacitidine, bazedoxifene acetate, benztropine mesylate, bortezomib, candesartan cilexetil, cetirizine, citalopram, darifenacin, dextromethorphan, famotidine, and ketorolac tromethamine. The company also develops generic biosimilar products and has four products in the market. The company also discovers, develops, manufactures and markets New Chemical Entities (NCEs) focusing on bacterial infections, metabolic disorders, pain and inflammation. The company markets products in over 75 countries in the US, Europe, Latin America and Asia. Dr. Reddy’s is headquartered in Hyderabad, Andhra Pradesh, India.

Dr. Reddy’s Laboratories Limited (EHP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Dr. Reddy’s Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 6
Dr. Reddy’s Laboratories Limited, Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014 7
Dr. Reddy’s Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 8
Dr. Reddy’s Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 9
Dr. Reddy’s Laboratories Limited, Medical Devices Deals, 2008 to YTD 2014 10
Dr. Reddy’s Laboratories Limited, Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014 11
Dr. Reddy’s Laboratories Limited, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Dr. Reddy’s Labs Completes Acquisition Of Oral Penicillin Facility And Product Portfolio From GlaxoSmithKline 15
GlaxoSmithKline Acquires Certain Assets Of Dr. Reddy’s 17
Dow Chemical Sells Its Dowpharma Small Molecules Business 18
Dr. Reddy’s Acquires Contract Manufacturing Business From BASF 19
Partnerships 20
Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 20
Oceana Therapeutics Enters Into Distribution Agreement With Dr. Reddy’s Labs For Deflux 21
OctoPlus Enters Into Co-Development Agreement With A BioPharma Company 22
OctoPlus Extends Co-Development Agreement With ESBATech 23
Argenta Discovery Enters Into Collaboration With Dr. Reddy’s Labs 24
SoluBest Enters Into Collaboration With Dr. Reddy’s Labs 25
Aurigene Enters Into Research Agreement With Pcovery 26
Alchemia Expands Co-Marketing Agreement With Dr Reddy’s Labs 27
OctoPlus Enters Into Drug Development Agreement With The Medicines Company 28
OctoPlus Enters Into Co-Development Agreement With Novartis 29
GlaxoSmithKline Enters Into Co-Marketing Agreement With Dr. Reddy’s Labs 30
Natco Pharma Enters Into Agreement With Dr Reddy’s Labs 31
Endo Pharma Partners With Aurigene Discovery Technologies 32
Dr. Reddy’s Enters Into Co-Marketing Agreement With Schering And Sepracor 33
Antares Pharma Enters Into Agreement With Dr. Reddy’s Labs 34
Dr. Reddy’s Labs Signs An Agreement With Albemarle 35
Dr. Reddy’s Labs Signs An Agreement With 7TM Pharma 36
Licensing Agreements 37
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 37
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy’s Labs For NeuVax 39
IsoRay Enters Into Licensing Agreement With Dr. Reddy’s Labs For Iotrex 40
Debiopharm Enters Into Option Licensing Agreement With Aurigene Discovery Technologies For Debio 1142 41
Dr. Reddy’s Labs Enters Into Licensing Agreement With R-Pharm 42
Dr. Reddy’s Labs Enters Into Licensing Agreement With Cipla 43
Dr Reddy’s Labs Enters Into Licensing Agreement With Vitabiotics 44
OctoPlus Enters Into License Agreement With A US Biotech Company 45
Aegis Therapeutics Enters Into Licensing Agreement With Dr. Reddy’s Labs 46
Transgene Biotek Enters Into Licensing Agreement With Dr Reddy’s Labs 47
Dr. Reddy’s Labs Enters Into Licensing Agreement With Cymbiotics For DIAPERESE 48
Debiopharm Enters Into Licensing Agreement With Aurigene 49
Biolex Therapeutics Enters Into Licensing Agreement With Octoplus 50
Cosmederm Technologies Enters Into An Agreement With Dr. Reddy’s Labs 51
Aquapharm Enters Into Licensing Agreement With Dr. Reddy’s Labs 52
Equity Offering 53
Octoplus Completes First Tranche Of Private Placement Of Common Stock For US$1.6 Million 53
Octoplus Completes Private Placement Of Common Stock For US$5.5 Million 54
OctoPlus Completes Private Placement Of US$5 Million 56
OctoPlus Completes Private Placement Of Shares For US$5.76 Million 58
OctoPlus Completes Private Placement Of US$7.55 Million 60
Acquisition 62
Dr Reddy’s Labs Acquires 98.6% Stake In OctoPlus 62
Dr. Reddy’s Labs Acquires Stake In Perlecan Pharma From Citigroup, ICICI And IDBI 65
Dr. Reddy’s Acquires Jet Generici 67
Dr. Reddy’s Laboratories Limited – Key Competitors 68
Key Employees 69
Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List of Tables
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Key Facts, 2014 1
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 1
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 1
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 1
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 6
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014 7
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 8
Dr. Reddy's Laboratories Limited, Deals By Therapy Area, 2008 to YTD 2014 9
Dr. Reddy's Laboratories Limited, Medical Devices Deals, 2008 to YTD 2014 10
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014 11
Dr. Reddy’s Labs Completes Acquisition Of Oral Penicillin Facility And Product Portfolio From GlaxoSmithKline 15
GlaxoSmithKline Acquires Certain Assets Of Dr. Reddy’s 17
Dow Chemical Sells Its Dowpharma Small Molecules Business 18
Dr. Reddy’s Acquires Contract Manufacturing Business From BASF 19
Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 20
Oceana Therapeutics Enters Into Distribution Agreement With Dr. Reddy’s Labs For Deflux 21
OctoPlus Enters Into Co-Development Agreement With A BioPharma Company 22
OctoPlus Extends Co-Development Agreement With ESBATech 23
Argenta Discovery Enters Into Collaboration With Dr. Reddy’s Labs 24
SoluBest Enters Into Collaboration With Dr. Reddy's Labs 25
Aurigene Enters Into Research Agreement With Pcovery 26
Alchemia Expands Co-Marketing Agreement With Dr Reddy's Labs 27
OctoPlus Enters Into Drug Development Agreement With The Medicines Company 28
OctoPlus Enters Into Co-Development Agreement With Novartis 29
GlaxoSmithKline Enters Into Co-Marketing Agreement With Dr. Reddy's Labs 30
Natco Pharma Enters Into Agreement With Dr Reddy's Labs 31
Endo Pharma Partners With Aurigene Discovery Technologies 32
Dr. Reddy's Enters Into Co-Marketing Agreement With Schering And Sepracor 33
Antares Pharma Enters Into Agreement With Dr. Reddy's Labs 34
Dr. Reddy's Labs Signs An Agreement With Albemarle 35
Dr. Reddy's Labs Signs An Agreement With 7TM Pharma 36
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 37
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax 39
IsoRay Enters Into Licensing Agreement With Dr. Reddy’s Labs For Iotrex 40
Debiopharm Enters Into Option Licensing Agreement With Aurigene Discovery Technologies For Debio 1142 41
Dr. Reddy’s Labs Enters Into Licensing Agreement With R-Pharm 42
Dr. Reddy's Labs Enters Into Licensing Agreement With Cipla 43
Dr Reddy's Labs Enters Into Licensing Agreement With Vitabiotics 44
OctoPlus Enters Into License Agreement With A US Biotech Company 45
Aegis Therapeutics Enters Into Licensing Agreement With Dr. Reddy's Labs 46
Transgene Biotek Enters Into Licensing Agreement With Dr Reddy's Labs 47
Dr. Reddy's Labs Enters Into Licensing Agreement With Cymbiotics For DIAPERESE 48
Debiopharm Enters Into Licensing Agreement With Aurigene 49
Biolex Therapeutics Enters Into Licensing Agreement With Octoplus 50
Cosmederm Technologies Enters Into An Agreement With Dr. Reddy's Labs 51
Aquapharm Enters Into Licensing Agreement With Dr. Reddy's Labs 52
Octoplus Completes First Tranche Of Private Placement Of Common Stock For US$1.6 Million 53
Octoplus Completes Private Placement Of Common Stock For US$5.5 Million 54
OctoPlus Completes Private Placement Of US$5 Million 56
OctoPlus Completes Private Placement Of Shares For US$5.76 Million 58
OctoPlus Completes Private Placement Of US$7.55 Million 60
Dr Reddy's Labs Acquires 98.6% Stake In OctoPlus 62
Dr. Reddy's Labs Acquires Stake In Perlecan Pharma From Citigroup, ICICI And IDBI 65
Dr. Reddy’s Acquires Jet Generici 67
Dr. Reddy's Laboratories Limited, Key Competitors 68
Dr. Reddy's Laboratories Limited, Key Employees 69
Dr. Reddy's Laboratories Limited, Subsidiaries 70

List of Figures
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 1
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 6
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 7
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 8
Dr. Reddy's Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 9
Dr. Reddy's Laboratories Limited, Medical Devices Deals, 2008 to YTD 2014 10

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GDPH28920D )"Dr. Reddy’s Laboratories Limited (EHP)(製薬・医療分野):企業のM&A・提携動向" (英文:Dr. Reddy's Laboratories Limited (EHP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)はGlobalData社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。